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BRIEF SUMMARY STATEMENT 
We found severe atrophy in all layers of the retina, retinal pigment epithelium/Bruch’s 
membrane, and choroid in the macular region in Bietti crystalline dystrophy patients 
with CYP4V2 mutations, while only the retina was severely atrophic in retinitis 






































































To compare atrophy of the choroid and retina between Bietti crystalline dystrophy 
(BCD) patients and EYS-related retinitis pigmentosa (RP) patients with a similar 
degree of central visual field defects, age, and axial length (AL). 
Methods 
Nine eyes of nine BCD patients with CYP4V2 mutations (BCD group) were examined. 
Moreover, we selected ten eyes of ten RP patients with EYS mutations matched for 
age, AL, and mean deviation (measured with the 10-2 SITA standard program; 
EYS-RP group), and ten eyes of ten normal volunteers matched for age and AL 
(control group). Macular thicknesses of the choroid and retina were measured via 
swept-source optical coherence tomography. 
Results 
The macular choroid was significantly thinner in the BCD group than in the EYS-RP 
and control groups, although the thickness did not significantly differ between the 
EYS-RP and control groups. The macular retina was significantly thinner in the BCD 
and EYS-RP groups than in the control group, although the thickness did not 
significantly differ between the BCD and EYS-RP groups at most sites. 
Conclusion 
BCD patients with CYP4V2 mutations showed more severe macular choroid atrophy 
as compared to EYS-related RP patients. These different damage patterns suggest 





































































Bietti crystalline dystrophy (BCD) is a rare retinal dystrophy characterized by the 
presence of yellow and shiny deposits on the cornea and posterior pole of the retina, 
along with progressive atrophy of the retina, choriocapillaris, and choroid.1 A 
long-term follow-up study showed that the formation of retinal crystals is followed by 
gradual atrophy of the retinal pigment epithelium (RPE) and constriction of the visual 
field.2 BCD is caused by mutations of the CYP4V2.3 The phenotype of 
CYP4V2-related BCD is highly variable4 and the mechanisms underlying the 
pathological changes in BCD remain unclear because of the rarity of the disease; 
therefore, no efficacious treatment is currently available. 
 The symptoms of BCD, including night blindness and progressive constriction 
of the visual field, are similar to those of retinitis pigmentosa (RP). However, gene 
expression patterns of CYP4V2 and the causative genes for RP are reportedly 
different. In particular, CYP4V2 is expressed in the retina and RPE in the eyes.3 
Although the RPE is generally thought to be the site of the primary pathological 
abnormality in BCD patients with CYP4V2 mutations, Nakano et al. showed weak 
staining of ganglion cells and internal/external nuclear layers in the retina by 
immunohistochemical staining.5 Their figure also suggested CYP4V2 expression in 
the choroid. In contrast, the human gene EYS, which is the most frequently mutated 
gene in Japanese RP patients,6, 7 encodes a protein that is localized in the outer 
segments of photoreceptors.8 Thus, the difference in expression patterns of the 
causative genes is responsible for the degree and the timing of the damage to each 
neuroretinal and choroidal layer. 
 Although the degenerative changes in RP mainly occur in photoreceptor cells, 
Dhoot et al. reported that the macular choroidal thickness was significantly decreased 
in patients with RP.9 The precise mechanism of choroidal thinning in RP is unclear. 
However, several studies have shown that the death of RPE cells secondary to the 
death of photoreceptor cells is implicated in choriocapillary atrophy.10, 11 In fact, 
vascular endothelial growth factor (VEGF) is produced by the RPE and is necessary 
for choroidal maintenance12; therefore, a lack of VEGF due to an RPE disorder may 
play a role in choroidal thinning. Recently, Saatoci et al. demonstrated the thinning of 
the retina and choroid in BCD.13 Considering the differences in the sites of expression 
of the causative gene between BCD and EYS-related RP, we believe that the degree 
and timing of the damage to each neuroretinal layer and choroid layer may differ 
between these two diseases. In the present study, we compared the presence of 
macular atrophy of the retina, RPE/Bruch's membrane (BM), and choroid between 







































































This study was approved by the ethics committee of Kyoto University, Graduate 
School of Medicine (Kyoto, Japan) and adhered to the tenets of the Declaration of 
Helsinki. The nature of the study and the possible consequences of participation were 




Consecutive patients with retinal degenerative disease or retinal dystrophy who 
visited the Department of Ophthalmology and Visual Sciences at Kyoto University 
Graduate School of Medicine (Kyoto, Japan) between January 2011 and October 
2015 were recruited to participate in the study. All patients provided blood samples for 
the detection of gene mutations. All participants also underwent a comprehensive 
ophthalmologic examination, including measurement of best-corrected visual acuity 
(BCVA) with a Landolt C chart and axial length (AL) with an IOL Master (Carl Zeiss 
Meditec). All BCVA data were converted to the logarithm of the minimal angle of 
resolution (logMAR) for statistical analysis. Slit-lamp biomicroscopy, indirect 
ophthalmoscopy, color fundus photography (TRC-NW8F; Topcon Corp, Tokyo, 
Japan), fundus autofluorescence (FAF) with an Optos device (Optos PLC, Scotland, 
United Kingdom), spectral domain optical coherence tomography (SD-OCT, 
Spectralis; Heidelberg Engineering, Dossenheim, Germany), swept source optical 
coherence tomography (SS-OCT, Topcon Corp., Tokyo, Japan), mean deviation (MD) 
measurements with a Humphrey field analyzer (HFA; Carl Zeiss Meditec, Dublin, CA) 
with the 10-2 Swedish Interactive Threshold Algorithm standard program for the 
evaluation of macular sensitivity, and 30-Hz flicker electroretinography (ERG) were 
also performed. ERG results were recorded according to the International Society for 
Clinical Electrophysiology of Vision standard protocol recommended in 2008 with the 
LS-C (Mayo Co., Nagoya, Japan) and Neuropack MEB-2204 systems (Nihon Kohden, 
Tokyo, Japan).14 With regard to inclusion criteria, we enrolled BCD patients with 
CYP4V2 mutations and with clear SD-OCT and SS-OCT images available. A clinical 
diagnosis of BCD was made based on the presence of characteristic fundus 
crystalline deposits, retino-choroidal dystrophy, and patchy RPE atrophy, whereas 
CYP4V2 mutations were detected via Sanger sequencing. The exclusion criteria 
were as follows: missing necessary data and the presence of other eye diseases 
except for refractive errors, cataract, and pseudophakia. When both eyes in one 
patient met the criteria, one eye was randomly selected for analysis. We also 




































































sequencing6 who were selected to be matched for age, AL, and MD among the 
consecutive patients, as well as Japanese volunteers with no eye disease except for 
refractive errors who were matched for age and AL. The BCVA of the volunteers was 
20/20 or better. 
 
SS-OCT measurement of choroidal and retinal thicknesses  
For choroidal and retinal thickness measurements, we acquired horizontal and 
vertical B-scan images through the fovea with SS-OCT. The light source was a 
wavelength-sweeping laser with a tuning range of approximately 100 nm centered at 
1050 nm, which yielded an axial resolution in tissue of 8 μm. Trained examiners 
performed the SS-OCT examinations after pupil dilation. They achieved pupil 
centration during the scan by using an internal fixation target, which was confirmed 
through a built-in camera within the SS-OCT system. Choroidal and retinal 
thicknesses were measured with a built-in caliper tool. The outermost highly reflective 
retinal band comprised the RPE and BM.15 Retinal thickness was defined as the 
distance between the vitreoretinal interface and the outer border of the RPE/BM 
complex. Choroidal thickness was defined as the distance between the outer border 
of the RPE/BM complex and the chorioscleral interface (Figure 1). Each thickness 
was manually measured at the subfovea and at 0.5, 1.0, and 1.5 mm from the center 
of the fovea in the superior, temporal, inferior, and nasal quadrants (a total of thirteen 
points) with built-in caliper tool software and AL adjustment system. Central retinal 
thickness and subfoveal choroidal thickness measurements were made on horizontal 
and vertical scans, and the mean of the two measurements was used as a 
representative value. 
 
SD-OCT measurement of the RPE/BM thickness 
By using a previously described method,16 we measured the thickness of the 
RPE/BM complex on horizontal and vertical B-scan images through the fovea, 
obtained with SD-OCT, as the axial resolution of SS-OCT (8 μm) is higher than that of 
SD-OCT(4–6 μm), which is adequate to measure a thin RPE/BM complex.17 At each 
location of interest on the retina, we acquired 100 SD-OCT images and averaged 
them to reduce speckle noise. Thereafter, we manually measured the thickness of the 
RPE/BM complex at the same subfoveal and macular sites described above with the 
built-in caliper tool software and AL adjustment system. The representative subfoveal 
value was calculated as the mean of the horizontal and vertical measurements. 
 
Statistical analysis 




































































analysis of variance was performed to compare the three groups. Corrections for 
multiple comparisons were made with a Tukey test. Comparisons of differences 
between the two groups, including age, AL, and MD matching, were performed using 
t-tests. We analyzed the correlations of the thickness values of the choroid, RPE/BM 
complex, and retina with age by using Pearson's rank correlation coefficient. The 
above statistical analyses were performed using SPSS version 21 (IBM, New York, 
NJ, USA). The cut-off value for subfoveal choroidal thickness, the best sensitivity–
specificity balance, and the area under the receiver operating characteristic curve 
(AUROC) were calculated using MedCalc version 12 (MedCalc Software, Ostend, 
Belgium). A P-value of < .05 was considered statistically significant. 
 
RESULTS 
A total of nine eyes of nine Japanese BCD patients with CYP4V2 mutations (five 
women and four men; BCD group); 10 eyes of 10 Japanese RP patients with EYS 
mutations who were matched for age, AL, and MD (four women and six men; EYS-RP 
group); and 10 healthy eyes of 10 Japanese volunteers (seven women and three 
men; control group) were included in this study. The characteristics of the study 
population are shown in Table 1 and clinical characteristics of the BCD group and 
EYS-RP group are shown in Table 2. The mean ages of the BCD group, EYS-RP 
group, and control group were not significantly different (BCD group vs EYS-RP 
group, P = .31; BCD group vs control group, P = .36; and EYS-RP group vs control 
group, P = .82). The mean AL was not significantly different between the groups (BCD 
group vs EYS-RP group, P = .92; BCD group vs control group, P = .80; and EYS-RP 
group vs control group, P = .93). The mean MD was not significantly different between 
the BCD group and EYS-RP group (P = .17). 
 
Choroidal thickness 
The mean subfoveal choroidal thicknesses in the BCD, EYS-RP, and control groups 
were 109.6 ± 30.3, 251.8 ± 55.2, and 285.7 ± 91.7 μm, respectively (Table 3). The 
macular choroid in the BCD group was significantly thinner than that in the control 
group at all sites and that in the EYS-RP group at all sites, except for the nasal site, 
1.5 mm from the fovea. In contrast, there were no significant differences in the 
macular thickness of the choroid between the EYS-RP group and control group at all 
sites. 
 
RPE/BM complex thickness 
The mean subfoveal RPE/BM complex thicknesses in the BCD, EYS-RP, and control 




































































were significant differences in complex thickness among the three groups at all 
thirteen sites. The RPE/BM complex was thinner in the BCD group than in the 
EYS-RP group and thinner in EYS-RP than in the control group. 
 
Retinal thickness 
The mean central retinal thicknesses in the BCD, EYS-RP, and control groups were 
117.9 ± 52.6, 180.3 ± 44.5, and 228.7 ± 22.4 μm, respectively (Table 5). Compared to 
the control group, the macular retina was significantly thinner in the BCD and EYS-RP 
groups at all sites. In contrast, the retinal thickness in the macular area of the BCD 
and EYS-RP groups was significantly different at only three sites. 
 
Choroidal thickness uniformity in the BCD and EYS-RP groups 
In the EYS-RP group, the choroid was significantly thinner at the nasal site, 1.5 mm 
from the fovea, than at the subfovea (P < .01) (Figure 2), and the choroid was 
significantly thinner nasal to the fovea than temporal to the fovea. However, no such 
difference was observed in the BCD group (P = .29). The choroidal thickness at 1.5 
mm temporal to the fovea was not significantly different compared to the subfoveal 
choroidal thickness both in the BCD and EYS-RP groups (P = .77 and P = .66, 
respectively). 
 
Differentiation of the BCD and EYS-RP groups by thickness analysis 
When the cut-off value for the subfoveal choroidal, subfoveal RPE/BM complex, and 
central retinal thicknesses were set at 156.5, 12, and 166 μm, respectively, we could 
distinguish between the BCD and EYS-RP groups with a sensitivity of 100% and 
specificity of 90%, with a sensitivity of 89% and specificity of 100%, and with a 
sensitivity of 89% and specificity of 70%, respectively. With regard to the AUROC, the 
best sensitivity–specificity balance achieved was 0.978, 0.967, and 0.833, 
respectively. 
 
Correlation between age and thickness 
There were no significant correlations between age and the thickness of the 
subfoveal choroid, subfoveal RPE/BM complex, and central retina in the BCD group 
(choroid, P = .60; RPE/BM, .66; and retina, .91, respectively) or in the EYS group 
(choroid, P = .51; RPE/BM, .09; and retina, .34, respectively). 
 
Differentiation of homozygotes and heterozygotes in the BCD group 
The mutations detected in the study patients are listed in Table 2. Among the nine 




































































mutations. All patients had at least one c.802-8_810del17inGC mutation which is 
known to cause deletion of exon 7. There were no significant differences in age (57.5 
± 6.6 vs 58.2 ± 4.7 years), MD (-30.9 ± 2.7 vs -28.8 ± 4.9 dB), subfoveal choroidal 
thickness (96.4 ± 19.6 vs 120.1 ± 35.1 μm), subfoveal RPE/BM complex thickness 
(10.5 ± 0.4 vs 12.0 ± 1.9 μm), and central retinal thickness (103.9 ± 40.2 vs 129.2 ± 
62.9 μm) between the cases with homozygous and compound heterozygous 
mutations (P = .22, .09, .15, .37, and .20, respectively). However, there was a 
significant difference in AL between them (24.4 ± 1.0 vs 24.1 ± 0.5 mm, P = .003). 
 
Novel mutations in CYP4V2 
We found two novel mutations (c.710C>A and c.1378T>C) in CYP4V2 by identifying 
the pathogenicity of the variants. These two variants were predicted as damaging by 
silico prediction programs (SIFT and Polyphen2), and were not found in the Japanese 
exome database (Human Genetic Variation Database, 
http://www.genome.med.kyoto-u.ac.jp/SnpDB/ [in the public domain]). 
 
DISCUSSION 
This study clearly showed that the macular choroid in the eyes of BCD patients with 
CYP4V2 mutations was significantly thinner than that in the eyes of RP patients with 
EYS mutations at a similar stage of visual field damage. The BCD group also had a 
thinner macular RPE/BM thickness as compared to the EYS-RP group. In contrast, 
the thickness of the macular retina did not markedly differ between the eyes of BCD 
patients with CYP4V2 mutations and the eyes of RP patients with EYS mutations, 
although the macular retina was significantly thinner in both the BCD group and 
EYS-RP group than in the control group. These findings suggest that pathological 
atrophy occurs simultaneously in the retina, RPE/BM, and choroid in BCD patients 
with CYP4V2 mutations. In the patients with EYS-RP, pathological atrophy occurs 
initially at the retina, followed by the RPE/BM and choroid. We matched participants 
according to MD values in the BCD and EYS-RP groups, and according to age and 
AL, as these parameters are associated with choroidal thickness in normal eyes.18 
 Li et al. reported that CYP4V2 is expressed in the retina and RPE.3 Another 
previous report also suggested expression of CYP4V2 in the choroid in their 
immunohistochemistry figure.5 In contrast, EYS is expressed in the outer segments of 
photoreceptors.8 The expression of CYP4V2 and EYS in the retina would cause 
retinal atrophy in the BCD and EYS-RP groups, respectively, consistent with our 
results; in particular, retinal thickness was decreased in the BCD and EYS-RP groups 




































































choroid could have led to the severe damage of the RPE/BM and choroid observed in 
the BCD group as compared to the EYS-RP and control groups. 
  A previous study reported that macular choroidal thickness was significantly 
decreased in patients with RP9, inconsistent with our findings. The mean subfoveal 
choroidal thickness was 251.8 ± 55.2 µm in the EYS-RP group in the present study 
and 245.6 ± 103 µm in the previous study, whereas the thickness of the controls was 
285.7 ± 91.7 μm in the present study and 337.8 ± 109 μm in the previous study. The 
differences in mean age (54.0 ± 11.2 versus 40.6 ± 12.9 years) and the possible 
difference in AL (mean spherical equivalent of −1.45 ± 2.61 diopters in the previous 
study and mean AL of 24.33 ± 1.26 mm in the present study) could explain these 
differences. The clinical findings of RP are variable because of the variability in the 
causative genes.19 This study focused on EYS mutations because EYS is a major 
causative gene of RP not only in Japanese,6, 7 but also in Spanish,20 British and 
Chinese,21 and Israeli and Palestinian populations.22 At present, the choroidal 
thickness in cases of RP with EYS mutations has not been thoroughly investigated. 
Hence, further studies investigating the choroidal thickness in EYS-RP at various 
disease stages are warranted. 
 Although BCD can be classified into early, intermediate, and advanced 
stages,23, 24 the choroidal thickness would not differ according to the stage and the 
choroid would become atrophic during the early stage. In the present study, the 
enrolled patients were at the early and intermediate stages and the mean subfoveal 
choroidal thickness of the BCD group was 107.5 ± 29.3 μm. A previous study reported 
that the mean subfoveal choroidal thickness was 95.37 ± 55.93 μm in intermediate- 
and late-stage BCD patients; however, the authors did not confirm the presence of 
CYP4V2 mutations.13 These values for the subfoveal choroidal thickness are 
substantially less than those in the controls. Furthermore, in the present study, case 4 
(early stage) had a subfoveal choroidal thickness of 75 μm and case 7 (intermediate 
stage) had a subfoveal choroidal thickness of 81 μm. These values are similar to the 
mean subfoveal thickness values of patients in the previous study at the intermediate 
and late stage (95.37 μm). In the present study, the cut-off value for the subfoveal 
choroidal thickness was set at 156.5 μm, which enabled the discrimination between 
BCD with CYP4V2 mutations and RP with EYS mutations (sensitivity of 100% and 
specificity of 90%). Therefore, it is important to monitor choroidal thickness, as it can 
be used an index for distinguishing BCD patients from EYS-RP patients even during 
the early stages. 
 Halford et al. reported that the phenotype was highly variable in BCD patients, 
and that deletions of exon 7 were associated with more severe disease.4 In the 




































































of exon 7; however, there was no significant difference in subfoveal choroidal atrophy, 
subfoveal RPE/BM complex atrophy, and central retinal atrophy between 
homozygotes and compound heterozygotes. The severity of the atrophy of the 
choroid, RPE/BM complex, and retina was similar between the patients who carried 
the c.802-8_810del17inGC mutation in the homozygous state and in the compound 
heterozygous state. However, we could not compare the severity between patients 
with deletion of exon 7 and with other mutations in the present study. 
 The distribution of the choroidal thickness may also help in distinguishing 
between BCD and RP with EYS mutations. The choroid was thinner in regions nasal 
to the fovea compared to regions temporal to the fovea in RP with EYS mutations; 
however, in BCD patients with CYP4V2 mutations, the choroidal thickness became 
uniformly atrophic. Hence, longitudinal studies on the progression of choroidal 
atrophy in these patients are needed to investigate the causes. 
 Retinal and RPE sheet transplantation is being suggested as a potential 
treatment method for degenerative diseases such as age-related macular 
degeneration and RP.25, 26 However, choroidal degeneration develops at the early 
stage of BCD and sheet transplantation of the choroid, along with the retina and RPE, 
would be necessary in those cases. Although retinal atrophy was confirmed in the 
BCD group, we recently reported that the cone photoreceptor cell density remained 
for visual dysfunction in BCD.27 Hence, sheet transplantation of the choroid and RPE 
might be sufficient for resolving BCD. Gene therapy is another option for BCD. In fact, 
gene therapy for severe retinal dystrophy has previously been reported,28-30 and 
would be beneficial for patients with CYP4V2 mutations at any stage of BCD. 
  This study has some limitations, including the cross-sectional design. The 
choroid, RPE/BM, and retina were significantly thinner even in the early-stage BCD 
patients than in the controls in this study. However, the choroid was not significantly 
thinner in the EYS-PR group than in the control group. In the EYS-RP group, retinal 
atrophy is the primary change observed, followed by atrophy of the photoreceptor 
cells and RPE/BM; finally, atrophy of the choroid occurs. A longitudinal study 
evaluating the choroidal, RPE/BM complex, and retinal thicknesses will aid in 
understanding the time course of structural changes in BCD patients with CYP4V2 
mutations and RP patients with EYS mutations. Moreover, the thicknesses were 
manually measured, which could have introduced errors. However, most previous 
studies have used manual measurements, and the reliability of these methods is 
generally accepted. Third, all BCD patients carried the c.802-8_810del17inGC 
mutation, which was reported to be associated with more severe phenotype, although 
we did not select the BCD patients. This mutation is most commonly found in 




































































without this specific mutation. 
 In conclusion, BCD patients with CYP4V2 mutations showed severe atrophy 
of the macular choroid, compared to the macular choroidal atrophy in RP patients 
with EYS mutations. These different patterns in damage suggested differences in the 
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Figure 1. Vertical swept source optical coherence tomography (SS-OCT) images and 
Heidelberg retina angiography images of eyes in Bietti crystalline dystrophy patients 
with CYP4V2 mutations, retinitis pigmentosa patients with EYS mutations, and 
control subjects.  
Left Top. Representative 30° Heidelberg retina angiography (HRA) infrared images of 
an eye of a patient with Bietti crystalline dystrophy with CYP4V2 mutations (Case 2) 
Sporadic crystalline deposits can be observed. The dots represent the measurement 
points at different distances from the fovea. 
Red, subfovea; green, 0.5 mm; yellow, 1.0 mm; blue, 1.5 mm 
Left Bottom. Representative 30° HRA autofluorescence images of a Bietti crystalline 
dystrophy patient with CYP4V2 mutations (Case 2) 
Patchy atrophy of the retinal pigment epithelium has spread. 
Right Top. Representative swept source optical coherence tomography (SS-OCT) 
images of an eye of a Bietti crystalline dystrophy patient with CYP4V2 mutations 
(Case 2) 
The thicknesses of the subfoveal choroid, subfoveal retinal pigment 
epithelium-Bruch's membrane (RPE-BM) complex, and central retina are 94, 12, and 
166 μm, respectively. The left side is superior and right-side is inferior. 
The summits of the triangles represent the measurement points at different distances 
from the fovea. 
Red, subfovea; green, 0.5 mm; yellow, 1.0 mm; blue, 1.5 mm  
Right Middle. Representative SS-OCT images of an eye of a retinitis pigmentosa 
patient with EYS mutations (Case 9) 
The thicknesses of the subfoveal choroid, subfoveal RPE-BM complex, and central 
retina are 273, 14, and 195 μm, respectively. 
Right Bottom. Representative SS-OCT images of a normal eye (56 year-old man; 
axial length, 24.69 mm) 
The thicknesses of the subfoveal choroid, subfoveal RPE-BM complex, and central 
retina are 363, 23, and 227 μm, respectively. 
 
Figure 2. Horizontal and vertical choroidal thickness differences according to specific 
sites between Bietti crystalline dystrophy patients with CYP4V2 mutations and 
retinitis pigmentosa patients with EYS mutations 
BCD group = Bietti crystalline dystrophy with CYP4V2 mutations group 
EYS-RP group = retinitis pigmentosa with EYS mutations group 
The bars indicate standard errors. 




































































Although the choroidal thickness at each site is comparable in Bietti crystalline 
dystrophy patients with CYP4V2 mutations, the choroid in retinitis pigmentosa 
patients with EYS mutations is thinner in regions nasal to the fovea than in regions 
temporal to the fovea. 
Bottom: Vertical changes in choroidal thickness 
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 Table 1. Characteristics of the study population. 
 BCD group EYS-RP group Control group 
n, eyes (patients) 9 eyes (9 patients) 10 eyes (10 patients) 10 eyes (10 patients) 
Female sex, eyes 5 eyes 4 eyes 7 eyes 
Age (years) 57.9 ± 5.3 52.7 ± 14.1 54.0 ± 11.2  
Visual acuity, logMAR 0.41 ± 0.37 0.73 ± 0.64 -0.10 ± 0.07 
AL (mm) 24.21 ± 0.72 24.27 ± 1.70 24.33 ± 1.26 
MD (dB) -29.77 ± 4.01 -26.13 ± 6.66  
BCD group: Bietti crystalline dystrophy patients with CYP4V2 mutations 
EYS-RP group: Retinitis pigmentosa patients with EYS mutations who were matched for age, AL, and MD with the 
BCD group.  
Control group: Japanese volunteers with no eye disease, except for refractive errors, who were matched for age and 
AL with the BCD group. 
Data are presented as mean ± standard deviation where applicable. 
AL = axial length; logMAR = logarithm of the minimal angle of resolution; MD = mean deviation measurements using 
a Humphrey field analyzer (Carl Zeiss Meditec, Dublin, CA) with the 10-2 Swedish Interactive Threshold Algorithm 
standard program. 
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Sex Eye BCVA AL (mm) HFA10-2 ERG (cone flicker) Mutation 








1 60 F L 20/20 24.66 −27.59 91.75 25.2 
c.802-8_810del17insGC 
/ c.327+1G>A 
2 58 F L 20/25 24.52 −33.18 15.7 29.2 
c.802-8_810del17insGC 
/ c.1378T>C* 
3 51 M R 20/250 23.52 −34.82 7.39 34 
c.802-8_810del17insGC 
/ c.710C>A* 
4 64 F R 20/40 23.93 −24.25 67.50 30.2 
c.802-8_810del17insGC / 
c.1226-6_1235del16 
5 53 M R 20/100 25.35 −32.26 25.71 28.4 
c.802-8_810del17insGC 
homozygous 
6 65 F L 20/100 23.58 −30.62 extinguished 
c.802-8_810del17insGC 
homozygous 
7 51 F R 20/66 25.12 −33.56 extinguished 
c.802-8_810del17insGC 
homozygous 
8 61 M R 20/20 23.44 −27.21 6.64 37.8 
c.802-8_810del17insGC 
homozygous 
9 58 M R 20/40 23.73 −24.40 39.75 28.0 
c.802-8_810del17insGC 
/ c.518T>G 
EYS-RP group         
1 66 F R 20/222 22.55 −33.36 extinguished c.4957dupA / c.7048delT 
2 49 F R 20/33 24.89 −24.04 extinguished 
c.5202_5203del 
/ c.8379_8380insTGCA 
3 45 F R 20/100 23.08 −30.07 extinguished c.4957dupA / c.8805C>A 
4 79 F R 20/222 23.37 −32.41 N.A. c.4957dupA / c.8805C>A 
5 34 M R 20/29 28.03 −14.41 extinguished c.4957dupA  homozygous 
6 51 M L 20/200 26.2 −31.06 extinguished c.9209T>C / c.4957dupA 
7 34 M L 20/13 24.24 −17.53 N.A. c.4957dupA / c.5014C>T 
8 64 M R 20/222 23.21 −31.77 extinguished c.7919G>A  homozygous 
9 56 M L 20/1000 23.08 −24.78 extinguished c.8805C>A / c.5014C>T 
10 49 M R 20/22 24.01 −21.91 extinguished c.4957dupA / c.8805C>A 
AL = axial length; BCD group = Bietti crystalline dystrophy with CYP4V2 mutations group; BCVA = best-corrected visual acuity; ERG = 
electroretinography; EYS-RP group = retinitis pigmentosa with EYS mutations group; F = female; HFA10-2 = Humphrey field analyzer with the 
10-2 SITA standard program; L = left eye; N.A.= not available; M = male; MD = mean deviation; R = right eye 
* novel mutation 
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 Table 3. Macular choroidal thickness in Bietti crystalline dystrophy patients with CYP4V2 mutations and retinitis 



















Subfovea 109.6 ± 30.3 251.8 ± 55.2 285.7 ± 91.7 < .001* < .001* .49 
Superior       
  0.5 mm 115.2 ± 25.1 248.9 ± 70.4 306.9 ± 99.7 .001* < .001* .20 
  1.0 mm 118.0 ± 28.7 247.5 ± 48.5 306.9 ± 96.8 .001* < .001* .13 
  1.5 mm 114.6 ± 27.6 243.7 ± 47.3 317.2 ± 104.1 .001* < .001* .06 
Temporal       
  0.5 mm 112.6 ± 31.2 255.6 ± 53.1 291.0 ± 88.9 < .001* < .001* .44 
  1.0 mm 110.0 ± 35.0 254.2 ± 46.6 286.5 ± 75.6 < .001* < .001* .41 
  1.5 mm 112.8 ± 41.8 246.6 ± 54.7 289.2 ± 60.1 < .001* < .001* .19 
Inferior       
  0.5 mm 117.9 ± 31.8  251.6 ± 59.9 280.2 ± 87.9 < .001* < .001* .59 
  1.0 mm 111.4 ± 35.8 239.5 ± 59.0 273.1 ± 89.9 .001* < .001* .50 
  1.5 mm 114.1 ± 35.7 221.4 ± 59.8 261.1 ± 78.1 .002* < .001* .33 
Nasal       
  0.5 mm 109.1 ± 26.3 237.0 ± 60.5 267.9 ± 97.8 .001* < .001* .59 
  1.0 mm 105.6 ± 22.0 213.7 ± 57.8 273.8 ± 115.1 .01* < .001* .21 
  1.5 mm 99.3 ± 18.9 174.5 ± 61.3 258.2 ± 125.8 .14 .001* .08 
BCD group: Bietti crystalline dystrophy patients with CYP4V2 mutations 
EYS-RP group: Retinitis pigmentosa patients with EYS mutations who were matched for age, AL, and MD with the 
BCD group.  
Control group: Japanese volunteers with no eye disease except refractive errors who were matched for age and AL 
with the BCD group. 
Data are presented as mean ± standard deviation (μm) where applicable. 
AL = axial length 
aAsterisk indicates statistical significance. 
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 Table 4. Macular retinal pigment epithelium/Bruch’s membrane complex thickness in Bietti crystalline dystrophy 



















Subfovea 11.3 ± 1.6 17.9 ± 3.6 23.5 ± 2.0 < .001* < .001* < .001* 
Superior       
  0.5 mm 10.2 ± 2.1 15.1 ± 5.1 23.5 ± 3.0 .02* < .001* < .001* 
  1.0 mm 9.1 ± 1.5 15.3 ± 5.0 22.5 ± 1.6 .001* < .001* < .001* 
  1.5 mm 9.3 ± 1.0 14.6 ± 5.7 23.3 ± 2.7 .01* < .001* < .001* 
Temporal       
  0.5 mm 9.6 ± 1.3 16.4 ± 4.9 23.0 ± 2.4 < .001* < .001* < .001* 
  1.0 mm 9.8 ± 1.9 13.7 ± 4.5 22.6 ± 2.2 .02* < .001* < .001* 
  1.5 mm 9.3 ± 1.0 13.1 ± 5.2 23.3 ± 1.6 .04* < .001* < .001* 
Inferior       
  0.5 mm 10.4 ± 1.3 15.5 ± 5.7 23.4 ± 2.8 .02* < .001* < .001* 
  1.0 mm 9.8 ± 1.6 14.1 ± 5.0 22.8 ± 1.8 .02* < .001* < .001* 
  1.5 mm 9.6 ± 1.7 13.6 ± 4.5 22.3 ± 2.1 .02* < .001* < .001* 
Nasal       
  0.5 mm 10.6 ± 0.9 17.8 ± 4.7 25.1 ± 2.4 < .001* < .001* < .001* 
  1.0 mm 9.8 ± 1.2 14.6 ± 5.4 24.3 ± 2.2 .02* < .001* < .001* 
  1.5 mm 9.6 ± 1.3 14.1 ± 5.0 23.1 ± 1.5 .01* < .001* < .001* 
BCD group: Bietti crystalline dystrophy patients with CYP4V2 mutations 
EYS-RP group: Retinitis pigmentosa patients with EYS mutations who were matched for age, AL, and MD with the 
BCD group.  
Control group: Japanese volunteers with no eye disease except refractive errors who were matched for age and AL 
with the BCD group. 
Data are presented as mean ± standard deviation (μm) where applicable. 
AL = axial length 
aAsterisk indicates statistical significance. 
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 Table 5. Macular retinal thickness in Bietti crystalline dystrophy patients with CYP4V2 mutations and retinitis 



















Center 117.9 ± 52.6 180.3 ± 44.5 228.7 ± 22.4 .01* < .001* .04* 
Superior       
  0.5 mm 219.6 ± 57.0 241.4 ± 34.6 298.3 ± 20.5 .46 .001* .009* 
  1.0 mm 256.6 ± 45.8 285.6 ± 25.1 339.6 ± 16.7 .12 < .001* .002* 
  1.5 mm 243.0 ± 48.0 282.7 ± 45.0 330.0 ± 16.3 .09 < .001* .03* 
Temporal       
  0.5 mm 193.8 ± 59.4 226.2 ± 30.2 289.5 ± 20.7 .19 < .001* .004* 
  1.0 mm 228.7 ± 62.6 246.1 ± 19.7 317.4 ± 16.8 .58 < .001* .001* 
  1.5 mm 204.6 ± 61.3 240.2 ± 26.1 308.0 ± 17.5 .13 < .001* .002* 
Inferior       
  0.5 mm 191.8 ± 61.1 224.5 ± 27.9 289.2 ± 22.3 .19 < .001* .003* 
  1.0 mm 214.9 ± 54.3 257.6 ± 21.2 333.2 ± 16.6 .03* < .001* < .001* 
  1.5 mm 201.9 ± 51.8 243.6 ± 28.9 322.0 ± 19.4 .04* < .001* < .001* 
Nasal       
  0.5 mm 204.4 ± 51.3 233.6 ± 42.8 299.2 ± 28.2 .29 < .001* .004* 
  1.0 mm 267.4 ± 36.0 272.1 ± 32.0 335.0 ± 15.9 .94 < .001* < .001* 
  1.5 mm 276.9 ± 43.9 274.4 ± 31.3 336.9 ± 16.9 .98 .001* .001* 
BCD group: Bietti crystalline dystrophy patients with CYP4V2 mutations 
EYS-RP group: Retinitis pigmentosa patients with EYS mutations who were matched for age, AL, and MD with the 
BCD group.  
Control group: Japanese volunteers with no eye disease except refractive errors who were matched for age and AL 
with the BCD group. 
Data are presented as mean ± standard deviation (μm) where applicable. 
AL = axial length 
aAsterisk indicates statistical significance. 
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